Fig. 5
From: Immune checkpoint inhibitors for multiple myeloma immunotherapy
A The combination of bonadomide, lenalidomide and ICIs showed great therapeutic efficacy in myeloma cells. B Carfilzomib enhanced the efficacy of PD-1 in egulating the bone marrow microenvironment and played a role in eliminating the tumor. C The combination of MM-specific antibodies and ICIs may have potential role in the treatment efficacy for MM. D Studies have combined CAR-T therapy with PD-1 blockade and have shown good therapeutic efficacy